Navigation Links
Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
Date:7/20/2009

Hygeia Therapeutics has added to its portfolio of topical hormonal modulators with the acquisition of a series of potent topical anti-androgens. The compounds are expected to be devoid of systemic activity and will be developed for skin and hair disorders associated with increased sensitivity to androgens.

Holden, MA (PRWEB) July 20, 2009 -- Hygeia Therapeutics Inc. (the "Company" or "Hygeia") today announced that it has enhanced its pipeline with the acquisition of a series of potent topical anti-androgens. The lead compound, HYG-440, is expected to lack systemic effects. The addition of the series of anti-androgens covering four different structural classes, adds to the Company portfolio of topically acting hormone receptor modulators. HYG-440 will undergo preclinical development for the treatment of androgen-dependent dermatological disorders such as acne, hirsutism and androgenic alopecia.

The anti-androgens were licensed from Yale University following approval of the transaction by Hygeia stockholders earlier this week. The asset acquisition, announced on July 16, 2009, is an important element of Hygeia's strategy for creating shareholder value. Hygeia shareholders will gain access to an important pipeline asset. Terms of the acquisition were not disclosed.

"We are excited about Hygeia's future, and are encouraged by the positive reaction we have received to this transaction from our investors, scientific advisory board and thought leaders in dermatology and women's health", said Yael Schwartz, Ph.D., President and Chief Executive Officer of Hygeia. "This acquisition combines decades of scientific experience, drug research, and success in discovering numerous promising topical drug candidates. It provides us with access to potentially lucrative corporate partnerships interested in safe and efficacious topical hormone modulators in the
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
4. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
5. New Report Just Published: World Prostate Cancer Therapeutics Market Report
6. King and Pain Therapeutics Announce REMOXY(R) NDA Update
7. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
8. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
9. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
10. PTC Therapeutics Receives $2.6 Million in Government Grants
11. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... news release is available in German . ... crystal around several quantum dots in a semiconductor layer. Quantum ... consequence of atomic processes. If a short laser pulse is ... and the quantum dot experiences a change in the electromagnetic ... down the emission of light by the dot. As soon ...
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... , Feb. 3 ERT (Nasdaq: ERES ), announced ... full year 2009 on Thursday, February 25, 2010 , after the ... at 5:00 PM EST that day. , For the ... United States or 1-412-858-4600 when calling internationally. There will be a ...
... GENEVA , February 3 Viroblock ... anti-viral products, today,announced that Dr. Jamie Paterson will join ... Jamie Paterson , a British national, can look back at 20 ... was,Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter ...
... Molecular Imaging Summit wrapped up today in Albuquerque, ... energy looking ahead. Nanotechnology is a quickly ... for applying technology in highly targeted ways. For ... target diseaseand treat many common and devastating diseases ...
Cached Biology Technology:ERT to Announce Fourth Quarter and Full Year 2009 Results on February 25, 2010 2Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2SNM's nanomedicine summit advances molecular imaging 2SNM's nanomedicine summit advances molecular imaging 3
(Date:10/1/2014)... take a healthy salad up a level by growing ... in leafy greens. , "In the long run, one ... the salad or making a pill from the plant ... at Case Western Reserve School of Medicine and leader ... cancer organization is funding the research with a three-year, ...
(Date:9/30/2014)... Mediterranean each year, but its deep-blue waters host ... 1,000 alien species, including fish, crustaceans, and algae ... activities. In the open-access journal Frontiers in ... analyzed data from a new information system developed ... introduction of alien species has changed the native ...
(Date:9/30/2014)... most comprehensive assessment conducted by the Ocean Health ... of 100 in overall health. In addition, for ... and the 15 ocean regions beyond national jurisdiction ... a healthy climate, safeguarding biodiversity and providing sustainable ... of the index, a partnership led by scientists ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2Rating the planet's oceans 2Rating the planet's oceans 3
... release is available in Spanish . , Barcelona, ... been discovered that neutrophils exist in the spleen without there ... group on the Biology of B Cells of IMIM (Hospital ... Sinai in New York, has also made it possible to ...
... imaging technologies and their contrast agents chemicals used during ... exposure to radiation or heavy metals, which present potential health ... applied. In an effort to mitigate these drawbacks, new research ... an iron-based contrast agent so that it only interacts with ...
... Calif., December 23, 2011 John C. Reed, M.D., Ph.D., ... Institute (Sanford-Burnham), have been named as Fellows of the American ... AAAS Fellow is an honor bestowed upon AAAS members by ... announced today in the AAAS News & Notes section of ...
Cached Biology News:Discovered the existence of neutrophils in the spleen 2Penn engineers develop more effective MRI contrast agent for cancer detection 2Penn engineers develop more effective MRI contrast agent for cancer detection 3AAAS and Sanford-Burnham announce 2011 fellows 2
... is a derivative of Taq DNA polymerase. ... aquaticus DNA polymerase. Expressed from a gene ... Met236, bypassing the 5'-3' exonuclease domain of ... a highly active and even more heat-stable ...
... Neogens enzyme-linked immunosorbent assay (ELISA) test ... screening devices for the detection of drugs ... kits are intended for forensic use only. ... be confirmed by a quantitative method such ...
... protein ribonuclease inhibitor that noncovalently binds and inactivates ... seen with RNase 1, T1, T2, H, U1, ... placental ribonuclease inhibitor in that it has a ... release active RNase in the absence of DTT ...
...
Biology Products: